Glycemia in acute coronary syndromes

被引:4
作者
Zeller, M.
Verges, B.
L'Huillier, I.
Brun, J. M.
Cottin, Y.
机构
[1] CHU Bocage, Serv Cardiol, Dijon, France
[2] CHU Bocage, Serv Endocrinol, Dijon, France
关键词
blood glucose; acute coronary syndrome; myocardial infarction; diagnosis; prognosis;
D O I
10.1016/S1262-3636(06)70485-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes is an established major factor of poor prognostis after an acute coronary syndrome. Recent studies have addressed the impact of abnormal glucose metabolism at the acute phase in patients without known diabetes. It has been found that abnormal glycemia regulation is more common than normal regulation in patients presenting with acute coronary syndrome, whatever the method used to evaluate blood glucose metabolism. High blood glucose at admission, whether fasting or not, are associated with worse outcome after an acute coronary syndrome, i.e. by increased mortality and development of severe heart failure. The prognosistic value of glycemia is valuable for both short and long term outcomes. Admission glycemia measurement allows therapeutic strategies at the acute phase. Fasting glycemia and oral glucose tolerance test performed during the hospital stay discloses valuable diagnostic information and provide useful tools for secondary prevention. Moreover, fasting glycemia is a more powerful predictor for short term outcome after myocardial infarction than admission glydemia. The mechanisms by which hyperglycemia deteriorates the cardiovascular prognosis, in particular for left ventricular dysfunction, are not fully understood. Stress hyperglycemia may be a marker of extensive cardiac damage, reflecting a surge of stress hormones such as catecholannines and cortisol that participate to insulinresistance and affect fatty acid and glucose homeostasis. Recent findings also argue for a direct deleterious effect of hyperglycemia on myocardium.
引用
收藏
页码:2S42 / 2S47
页数:6
相关论文
共 50 条
  • [41] The role of matrix metalloproteinases in acute coronary syndromes
    Dabek, Jozefa
    Kulach, Andrzej
    Gasior, Zbigniew
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2007, 18 (06) : 463 - 466
  • [42] Acute Coronary Syndromes: Differences in Men and Women
    Kris R. Kawamoto
    Melinda B. Davis
    Claire S. Duvernoy
    Current Atherosclerosis Reports, 2016, 18
  • [43] Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes
    Bhatt, Deepak L.
    Hulot, Jean-Sebastien
    Moliterno, David J.
    Harrington, Robert A.
    CIRCULATION RESEARCH, 2014, 114 (12) : 1929 - 1943
  • [44] Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes
    Elias B. Hanna
    David Luke Glancy
    Jorge F. Saucedo
    Cardiovascular Drugs and Therapy, 2010, 24 : 61 - 70
  • [45] Evaluation of Chest Pain and Acute Coronary Syndromes
    Chang, Anna Marie
    Fischman, David L.
    Hollander, Judd E.
    CARDIOLOGY CLINICS, 2018, 36 (01) : 1 - +
  • [46] Epidemiology of acute coronary syndromes in France and in Europe
    Danchin, N.
    Puymirat, E.
    Aissaoui, N.
    Adavane, S.
    Durand, E.
    ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE, 2010, 59 : S85 - S89
  • [47] Highlights of Acute Coronary Syndromes
    Recio-Mayoral, Alejandro
    EUROPEAN CARDIOLOGY REVIEW, 2022, 17
  • [48] Proteomics of acute coronary syndromes
    Athanasios Didangelos
    David Simper
    Claudia Monaco
    Manuel Mayr
    Current Atherosclerosis Reports, 2009, 11 : 188 - 195
  • [49] Hirudin in acute coronary syndromes
    van de Loo, A
    Bode, C
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (05) : 459 - 465
  • [50] Bivalirudin in acute coronary syndromes
    Galli, Mattia
    Bernardi, Marco
    Ortega-Paz, Luis
    Nerla, Roberto
    D'Amario, Domenico
    Franchi, Francesco
    Biondi-Zoccai, Giuseppe
    Angiolillo, Dominick J.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2023, 21 (12) : 901 - 911